Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared on LinkedIn:
“Excited to announce that I’ll be speaking at 2024 NCODA International Fall Summit (Orlando, Florida, October 23-25).”
More posts featuring Khalid El Bairi on oncodaily.com
Khalid El Bairi, founder of The Cancer Biomarkers Working Group, specializes in clinical and translational research in medical oncology. With many peer-reviewed articles, he delves into predictive and prognostic cancer biomarkers, especially for digestive and gynecological cancers like ovarian and colorectal malignancies. El Bairi holds board positions in international scientific societies such as IGCS, ESMO, ASCO, ESGO, and AACR. Serving as editor and reviewer for over 40 journals, he also educates medical and Ph.D. students on evidence-based medicine, research methodologies, and publishing ethics.